InVasc is an innovative, niche company focusing on pharmaceutical agents that aid in the treatment and prevention of atherosclerosis and related complications including heart attacks and stroke. The focus of the company is on conventional small molecule pharmaceuticals given their ease of production and scale-up technology without risk.

Product development at InVasc will follow a trajectory that ensures a thorough selection and development process for products in each platform; each of which will address multiple target pathways, be cost-effective, and reflect commitment to safety and efficacy.

InVasc prides itself on its ability to identify and develop novel compounds through pre-clinical and Phase I/II clinical trials with speed and efficiency. InVasc sees the completion of Phase II as the ‘sweet spot’ of drug development at which point revenue can be generated through licensing agreements with larger pharmaceutical entities.

By avoiding the large-scale costs and demands of Phase III studies and ultimate manufacture/marketing of the product, both InVasc and its investors will profit from the company’s desire to do what it does best…create and develop novel compounds.

TechColumbus

InVasc’s Founder’s, leading researchers from Emory University (Atlanta, GA) and Ohio State University (Columbus, OH), have been scientific collaborators for the last 15 years; they started the company in 2006.

InVasc bases its scientific facilities in Columbus, Ohio and keeps administrative offices in Atlanta, Georgia.